Objective: To investigate the relationship between anxiety symptoms and sleeping medication use among a nationally representative sample of US older adults.
benzodiazepine use in older patients with GAD. 15 Even antihistamines (eg, diphenhydramine), an over-the-counter alternative to benzodiazepines, have been associated with negative health outcomes in older adults (ie, greater risk of falls). 16 By establishing an association between anxiety symptoms and general sleeping medication use, clinicians may first consider nonpharmacological interventions for anxiety-related insomnia (eg, cognitive behavioral therapy) as opposed to sedating medications, which may reduce adverse drug events related to sedating medication.
Insomnia is intimately linked to anxiety and mood disorders. 17, 18 However, several studies report differences in the types of insomnia observed in anxiety compared to depression and their relationships to sleeping medication use. 19, 20 For example, one study assessing sleep quality 19 found that depression was associated with waking during the night and early morning, sleepiness during the day, and the use of a sleeping medication, while anxiety was associated with longer sleep latency and waking during the evening and early morning.
The authors posit that the observed differences in sleep quality, namely, longer sleep latency, may be due to, in part, the central nervous system activation and rumination that occurs in anxiety disorders. Similarly, another study also found that depressive symptoms, not anxiety, were associated with sleeping medication use after controlling for confounding. 20 Unlike Leblanc et al 19 and Potvin et al, 20 one study reported that depression and anxiety symptoms were associated with sleeping medication use. 21 Similarly, in a representative sample of US adults ages 18 to 75 years old, it was found that sleeping medication was associated with both anxiety and depressive disorders. 22 However, compared to 18 to 24 year olds, older adults, aged 65+ years, with anxiety did not exhibit greater odds of taking a sleeping medication.
To our knowledge, only one study has measured associations between anxiety disorders (GAD, posttraumatic stress disorder, and panic disorder), mood disorders (major depressive disorder and depressive symptoms), insomnia, and sleeping medications in older adults in the United States. 23 Although sedative-hypnotic sleeping medications were associated with every clinical group, similar to previous studies, only depressive symptoms remained a significant predictor after controlling for confounding. Against expectations, participants with GAD exhibited less sedative-hypnotic use than participants with major depressive disorder. However, as the authors noted, their study was limited because of a small sample size (total N = 483; N taking sedative-hypnotic = 125). In summary, unlike depression, the association between anxiety symptoms and sleeping medication use among older adults is unclear. Therefore, the present study aims to clarify the association between anxiety symptoms and sleeping medication use by utilizing a nationally representative sample of older adults. In addition to addressing a gap in the present literature, our study is also motivated by the clinical implications of older adults' use of sedating medications.
To address the inconsistency present in the literature and build upon previous research with small samples, we investigate the association between anxiety symptoms and sleeping medication use with a nationally representative sample of Medicare-eligible older adults in the United States. A major strength of the present study's data source, the National Health and Aging Trends Study (NHATS), is the oversampling of non-Hispanic Black Americans and oldest-old to obtain a more demographically diverse and representative image of the association between anxiety symptoms and sleeping medication use. 24 We hypothesize that there will be a significant association between anxiety symptoms and sleeping medication use. Our secondary objective is to explore sociodemographic, physical, and mental health variables that may also be associated with sleeping medication use in this sample. • Approximately 10 million older adults in the United
| METHODS
States have taken a sleeping medication in the last 30 days.
• Results identified a significant association between high anxiety symptoms and sleeping medication use in a nationally representative sample of US older adults.
• Depression, chronic conditions, and poor self-rated health were also significantly associated with sleeping medication use. Likert scale ("every night" [7 nights a week; n = 863]), "most nights"
[5-6 nights a week; n = 201], "some nights" [2-4 nights a week; n = 460), "rarely" [once a week of less; n = 547], and "never"
[n = 5077]). To create a binary variable, we combined responses indicating sleeping medication use ("every night," "most nights," "some nights," and "rarely"; n = 2071) and responses indicating no sleeping medication use ("never"; n = 5077).
| Mental health variables
The NHATS assesses anxiety symptoms with the Generalized Anxiety Disorder-2 (GAD-2) module. The GAD-2 is a 2-question standardized and validated measure of anxiety symptoms for both clinical and elderly populations. 27 The NHATS GAD-2 questions are "Over the last month, how often have you: a) felt nervous, anxious, or on edge; b) been unable to stop or control worrying?" Using a 4-point Likert scale scored from 0 to 3, respondent's response categories were "not at all,"
"several days," "more than half the days," and "everyday." Scores from the GAD-2 questions were summed to create a composite measure, ranging from 0 to 6. It has been previously identified that scores greater than or equal to 3 have a sensitivity of 86% and specificity of 83% for a GAD diagnosis. 27 Therefore, we specified anxiety as a binary variable with a GAD-2 score less than or equal to 2 identified as low anxiety and GAD-2 scores greater than or equal to 3 identified as high "several days," "more than half the days," and "everyday." Individual questions were scored from 0 ("not at all") to 3 ("everyday"). We summed scores on both of the PHQ-2 questions to create a composite score from 0 to 6. Similar to the GAD-2 module, it has been found that PHQ-2 scores greater than or equal to 3 have a sensitivity of 82.9%
and specificity of 90.0% for depression. 30 Therefore, depression was categorized into a binary variable using PHQ-2 scores greater or equal to 3 as a cut-off for high depressive symptoms.
| Additional measures
We adjusted for self-reported insomnia symptoms (ie, trouble falling back asleep after an early waking and taking over 30 minutes to fall asleep). Additional self-reported variables were identified to both describe the respondent sample and adjust for potential confounding (ie, age, biological sex, race/ethnicity, dementia diagnosis, selfreported health, and chronic conditions).
Respondents were asked (1) "In the last month, how often did it take you more than 30 minutes to fall asleep?" and (2) "In the last month, on nights when you woke up before you wanted to get up, how often did you have trouble falling back asleep?" Valid responses included, "every night (7 nights per week)," "most nights (5-6 nights per week)," "some nights (2-4 nights per week)," "rarely (once or less a week)," and "never." Similar to several other studies, chronic conditions and self-related health were included as relevant potential confounders. [20] [21] [22] The following chronic conditions were first recoded as binary variables of either having or not having the diagnosis: high blood pressure, heart disease, arthritis, osteoporosis, diabetes, and cancer. Each diagnosis was then summed to create a score of chronic conditions ranging from 0 to 6. Because of a low percentage of respondents with 5 (3.0%) and 6 (<1%) chronic conditions, 3 groups were created: (1) no chronic conditions (10.06%), (2) 1 to 3 chronic conditions (75.78%), and (3) 4 to 6 chronic conditions (14.16%). Lastly, a self-reported dementia diagnosis was also included as a potential confounder. 30 Respondents with invalid data ("don't know/refused to answer/missing") were excluded from analysis.
| Data analysis
For these analyses, we conducted a logistic regression to measure the association between sleeping medication use and anxiety symptoms after adjusting for potential confounders. We also included sociodemographic, physical, and mental health variables that have been shown to be related to sleeping medication use 20, 21, 23, 32 in our logistic regression model. Given the potential inaccuracies in self-reported data among individuals with cognitive impairment, we conducted a sensitivity analysis excluding participants with a dementia diagnosis (n = 457).
Specifically, we modeled the association between sleeping medication use and anxiety symptoms among community-dwelling respondents, adjusting for the same covariates as in the main model among the sample without a dementia diagnosis (n = 6,756). Sample estimates and comparisons are weighted to reflect the US population of older adults.
All statistical analyses were performed in STATA version 14.0. 33 
| RESULTS
Among 7148 community-dwelling NHATS respondents, 933 (13.1%)
were classified as having high anxiety and 2071 (29.0%) reported taking a sleeping medication. After applying population weights, it is estimated that 4 million community-dwelling older adults may have clinically significant generalized anxiety symptoms and 10 million take a sleeping medication. Table 1 stratifies sleeping medication use and other predictor variables by low and high anxiety. Expectedly, a large portion of respondents classified as high anxiety was also classified as having significant depressive symptoms (51.9%). Additionally, we observe significant gender differences across the low-and high-anxiety groups, with a greater proportion of females experiencing high anxiety (64.2%) compared to low anxiety (54.5%). The stratification also reveals noteworthy differences in demographic characteristics (eg, age, education, and race) the number of chronic illnesses, self-rated health, and insomnia across individuals with low and high anxiety.
Logistic regression results revealed several significant associations (Table 2 ). In support of our hypothesis, respondents with high anxiety symptoms had 2.60 (95% CI, 2.24-3.02) times the odds of taking a sleeping medication compared to individuals with low anxiety symptoms.
After adjusting for confounding, the effect of anxiety attenuates slightly but remains a significant predictor of sleeping medication use 142.73, P < .000
Notes: Chronic conditions represent a composite score, ranging from 0 to 6, of having a diagnosis of high blood pressure, heart disease, arthritis, osteoporosis, diabetes, and cancer, or not. Data were weighted to account for complex survey design and represent a sample of older adults living in the United States. Abbreviation: NHATS, National Health and Aging Trends Study a Anxiety was measured using the Generalized Anxiety Disorder-2 module. Scores less than or equal to 2 were considered low anxiety and scores greater than or equal to 3 were considered high anxiety.
b Depression was measured using the Patient Health Questionnaire-2 module. Scores less than or equal to 2 were considered low depression and scores greater than or equal to 3 were considered high depression. more than 30 minutes or trouble falling back asleep after waking, the greater their odds of sleeping medication use. Last, results from the sensitivity analysis suggest that the association between anxiety symptoms and sleeping medication use (AOR = 1.64; 95% CI, 1.33-2.01) persisted even after excluding individuals with a self-reported dementia diagnosis (results can be found in the online appendix).
| DISCUSSION
Our study has several key findings. First, among a national sample of older adults, respondents with high anxiety symptoms had significantly greater odds of sleeping medication use compared to older adults with low anxiety symptoms, even after adjusting for potential confounding.
Second, we replicated previous findings that have associated depressive symptoms with sleeping medication use. [19] [20] [21] [22] Third, a greater number of chronic health conditions, worse self-rated health, being female and White were also associated with increased odds of using sleeping medications. Interestingly, age did not emerge as a significant factor of sleeping medication use among our sample of older adults.
Last, results from the sensitivity analysis excluding respondents with dementia revealed the association between high anxiety symptoms and sleeping medication use persisted.
Studies of older adults living outside United States have inconsis-
tently identified anxiety symptoms as a predictor of sleeping medication use. [19] [20] [21] One study among the US general population did associate anxiety and sleeping medications, although did not identify age as a significant factor. 22 To our knowledge, this is among the first studies to identify a significant association between anxiety and sleeping medication use among a nationally representative sample of older adults living in the United States.
In addition to our primary aim, our results identified associations between depressive symptoms, the presence of chronic health conditions, and worse self-rated health as factors related to sleeping medication use. Therefore, surveying the presence or absence of the various predictors of sleeping medication use in older patients during a clinical interview may allow clinicians to identify older adults who may be at risk for sleeping medication use. Furthermore, the results from our work finding an association between sleep latency and 35 These ethnic differences may be attributed to, in part, differential reporting of sleeping problems with health care providers; however, future research is required to further understand this association. 35 As older adults tend to be more sensitive to the side effects of medications and are susceptible to adverse drug events related to polypharmacy, the use of nonpharmacologic interventions may be clinically beneficial. 36 Several studies have highlighted the effectiveness of cognitive behavioral therapy (CBT) for treating insomnia 37 and anxiety. 38 The CBT aims to identify and challenge dysfunctional thoughts related to sleep and its impact on function. 39, 40 Based on our findings, we suggest that future research examine whether or not patients with anxiety symptoms taking sleep medications may benefit from alternative and tailored nonpharmacological interventions, such as CBT.
It is worthy to note this study's limitations. First, we relied on self- The strength of the present study is largely the use of nationally representative data to extend findings to older adults throughout the United States. NHATS is a strong survey tool with a high response rate (87%) and deliberate oversampling of underrepresented ethnic populations and ages. Also, the large sample size with minimal missing and invalid data enables for more robust statistical analyses.
In summary, the present research adds to current literature by identifying anxiety symptoms as being significantly associated with sleeping medication use. We replicate previous findings asserting depressive symptoms, [20] [21] [22] other sociodemographic factors (eg, gender, education, and ethnicity), 21, 33 chronic conditions, and self-reported health as factors related to sleeping medication use. 22 Beyond the individual finding associating anxiety symptoms and sleeping medication use, we stress that all variables significantly associated with sleeping medication use must be considered when treating older patients because anxiety is rarely independent of other clinical, demographic, and socioeconomic factors. A thorough and comprehensive clinical interview identifying alternative treatment strategies for anxiety symptoms and anxiety-induced insomnia is likely to optimize and improve care for older patients.
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